FDA Investigating Disposable Gloves From Hundreds Of Foreign Companies Because Of Reprocessing Fears

Agency urges health care providers and other users to stop using the gloves

The US FDA says it’s “investigating certain imported medical gloves that appear to have been reprocessed, cleaned, or recycled and sold as new.” The 270 firms in question are listed on an import alert that says their gloves are subject to Detention without Physical Examination.

Doctor in a white coat with buttons shows a gesture of dislike with his hands, wearing blue medical gloves.
• Source: Alamy

The US Food and Drug Administration on 29 October called out 270 companies from 16 countries that the agency says may be selling disposable medical gloves that have already been used.

The FDA is “investigating certain imported medical gloves that appear to have been reprocessed, cleaned, or recycled and sold as new,” the agency said, adding that “many foreign manufacturers and shippers of medical gloves have failed to

More from Regulation

More from Policy & Regulation

‘Help Us Deregulate’: RFK Announces RFI For Trimming Government Health Agencies

 

HHS Secretary Robert F. Kennedy, Jr. is asking the public to help cut waste across the government’s health agencies. Kennedy announced a 60-day comment period allowing the public to take part in a broader federal initiative to reduce regulations and increase transparency.

MedTech Europe’s Bisazza Urges Action As US Tariffs Jeopardize Critical Global Supply Chains

 

The intricate assembly of medical devices, often involving over 1,000 globally sourced components, faces severe disruption due to new US tariffs. These barriers could halt production and devastate small and medium-sized enterprises (SMEs), MedTech Europe’s CEO, Oliver Bisazza, warns in an interview with Medtech Insight.

UK Medtech Regulators Must Ensure Certainty So Businesses Can Plan Their Futures

 
• By 

With medtech businesses typically managing investment cycles on a three- to five-year basis, local regulatory processes and forward costs of market entry must offer an attractive environment in which companies can plan for growth, says McDermott Will and Emery’s partner and head of healthcare and life sciences, Sharon Lamb. Broad-scale improvements to NICE’s evaluation offerings would similarly enhance the UK’s value to innovators.